Prokinetic Agents and Laryngopharyngeal Reflux Disease

s of all retrieved studies. The full text of the selected studies were then analyzed to ensure that the following inclusion criteria were met: prospective study design, a patient population with a diagnosis of LPR, treatment arm including a prokinetic agent with or without the concomitant use of an antacid therapy (e.g., PPI or H2 antagonist), presence of a comparison arm, and treatment outcomes available. References of the retained articles were reviewed to identify additional relevant articles that were not found with the initial search strategy. Data were independently extracted from each study by two authors and entered into a standardized database. Clinical data included treatment and control group demographic information, sample size, criteria for LPR diagnosis, intervention descriptions (e.g., doses and duration), and outcome parameters. Internal validity was assessed using the Cochrane risk of bias assessment tool for RCTs. The authors also assessed each study’s generalizability to other patient populations. All discrepancies between authors were resolved by group discussion and